Twitter Beğeni Hilesi

👉 Did you miss the second edition of the ESMO Virtual Journal Club? You can now access this in-depth review of three important publications by key opinion leaders. Watch now with your ESMO membership: 🔗 ow.ly/9zvg50SFa8A

🤔 How have CDK4/6i impacted the OS in first-line for HR+/HER2- advanced breast cancer? 📣 Delighted to share this editorial in Annals of Oncology, coauthored with Mafalda Oliveira annalsofoncology.org/article/S0923-…

Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) in advanced melanoma: systematic review and meta-analysis by George Coukos and coll. including patients pre and post anti-PD-(L)1 therapy annalsofoncology.org/article/S0923-…

📢 New paper from Katharine Collier, MD in Annals of Oncology "Confirmation of large BRCA2 reversion deletions leading to reconstituted in-frame transcripts detected via circulating tumor DNA" annalsofoncology.org/article/S0923-… The James Ohio State Medical Oncology

Just published in Annals of Oncology, a Letter to the Editor reviewing the crosstalk between the tumor microenvironment and cachexia, and suggesting therapeutic opportunities annalsofoncology.org/article/S0923-…

New study led by Dr. Rachel Freedman just published in Annals of Oncology looking at Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2+ #BreastCancerBrainMetastases Rachel Freedman, MD, MPH Nancy Lin, MD Heather Parsons Beverly Moy Dario Trapani Adam Brufsky pubmed.ncbi.nlm.nih.gov/38977064/

Following the ESMO - Eur. Oncology PMWG recommandations for the use of NGS 🧬 for patients with advanced cancer, this Letter to the Editor by Alice Rossi and coll. advocates for the use of molecular profiling in the management of HNSCC annalsofoncology.org/article/S0923-…

New article in press: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Toni Choueiri, MD Brian Rini, MD Robert Motzer MD

New article in press: A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance two years later. Antonio Di Meglio, MD, PhD; Ines Vaz Luis; Stefan Michiels; FabriceAndre; Unicancer; Gustave Roussy

New original article in press: Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Stefano Luminari, MD

I am honored to be serving as the Guest Editor for ESMO - Eur. Oncology GI special issue: "THE EVOLVING CHALLENGE OF #EARLYONSET #GI #CANCER" w/ editors-in-chief: Florian Lordick Prof. Irit Ben-Aharon. We look forward to articles of interest on: 🔹Biology 🔹Epidemiology 🔹Treatment 🔹Survivorship and

New article in press: The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development. Ben Westphalen FabriceAndre Vivek Subbiah, MD

Listen to the latest Annals of Oncology article of the Month podcast on the 5-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma: tinyurl.com/3nzuaxd4 Read the full article here doi.org/10.1016/j.anno…

New in press: Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial. Davide Ciardiello G Curigliano MD PhD doi.org/10.1016/j.anno…

Read the Sep. issue: ESMO CPG update on targeted therapies in the 1st line and at relapse of CLL Impact of HR status and tumor subtypes of BC in young BRCA carriers Amivantamab+lazertinib vs osimertinib in 1st-line EGFR-mutant adv NSCLC with biomarkers of high-risk disease

New article in press: Randomized phase 2 dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Neeraj Agarwal, MD, FASCO

📢 New European Hematology Association (EHA)–ESMO #ClinicalPracticeGuideline (CPG) on HIV-associated #lymphomas. Check it now: 🔗 ow.ly/xZ8v50TcXLL

New article in press: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. Jean-Yves Blay doi.org/10.1016/j.anno…